Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
Mwanasha H. Merrill(Dana-Farber Cancer Institute), David Qualls(Memorial Sloan Kettering Cancer Center), Robert Redd(Harvard University), Paolo F. Caimi(University Hospitals Seidman Cancer Center), Kami J. Maddocks(The Ohio State University), Priyanka Pullarkat(Massachusetts General Hospital), Richard Godby(Mayo Clinic), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Connie Lee Batlevi(Memorial Sloan Kettering Cancer Center), Michael J. Buege(Memorial Sloan Kettering Cancer Center), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Philippe Armand(Harvard University), Michelle Okwali(Memorial Sloan Kettering Cancer Center), Grzegorz S. Nowakowski(Université Claude Bernard Lyon 1), Brad S. Kahl(UW Health University Hospital), Jason T. Romancik(Emory University), Arushi Khurana(Mayo Clinic in Arizona), Graham T. Wehmeyer(Cornell University), Behzad Amoozgar(Washington University in St. Louis), Gilles Salles(Memorial Sloan Kettering Cancer Center), Jennifer L. Crombie(Dana-Farber Cancer Institute), Sarah C. Rutherford(NewYork–Presbyterian Hospital), Jeremy S. Abramson(Massachusetts General Hospital), Nicholas Lambert(Baylor College of Medicine), Lori A. Leslie(Hackensack University Medical Center)
Cited by 0
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k